StockData
Dermata Therapeutics, Inc. logo

Dermata Therapeutics, Inc. (DRMA) stock

DRMANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$0.53−0.01 (-1.50%)

Close on Nov 19, 2026Market cap $2.14MP/E –Yield –

Dermata Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Dermata Therapeutics

Dermata Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Dermata Therapeutics figures

See a number that looks wrong?